Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Airway pH Phenotyping with Glycine Buffer
NCT03617718Phase 2Completed
- Sponsor
- Case Western Reserve University
- Start
- Nov 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glycine buffer in asthma and cystic fibrosis (CF) (3 arms), sponsored by Case Western Reserve University. Primary endpoints: Changes in Fractional Exhaled Nitric Oxide levels, Frequency of shared phenotypic features among participants with low airway pH compared to those with low exhaled breath condensate (EBC) pH at 3 months and 3 more. Started Nov 2018; status: completed.
02
Drugs
glycine buffer
03
Conditions
asthmacystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03617718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617718.